Mark J. O’Connor

21.3k citations

119 papers · 13.7k · 5 hit papers · h-index 55

Impact in

Oncology top 0.1%
- PARP inhibition in cancer therapy
- Cancer-related Molecular Pathways
Reproductive Medicine top 0.5%
- Ovarian cancer diagnosis and treatment

Papers in

Oncology 86
- PARP inhibition in cancer therapy 61
- Cancer-related Molecular Pathways 11
- Metal complexes synthesis and properties 8
Molecular Biology 83
- DNA Repair Mechanisms 63
- CRISPR and Genetic Engineering 12
- Cancer therapeutics and mechanisms 10

Co-authors: Alan Lau (28 shared papers)Johann S. de Bono (2 shared papers)Alan Ashworth (2 shared papers)Andrew Tutt (2 shared papers)Timothy A. Yap (4 shared papers)Graeme C.M. Smith (7 shared papers)Yves Pommier (1 shared paper)Peijun Wu (1 shared paper)
Journals: Cancer Research (16 papers)Molecular Cancer Therapeutics (12 papers)Journal of Virology (6 papers)Clinical Cancer Research (5 papers)Journal of Clinical Oncology (4 papers)
Partner nations: United Kingdom United States Singapore

In The Last Decade

Mark J. O’Connor

114 papers receiving 13.5k citations

Mark J. O’Connor's Hit Papers

5 papers align trajectories log scale

Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action 2016 · 540 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2016 Science Translational Medicine
2015 Molecular Cell
2009 New England Journal of Medicine
2008 Proceedings of the National Academy of Sciences
2006 Cancer Research

Peers

Countries citing papers authored by Mark J. O’Connor

Since Specialization

Citations

This map shows the geographic impact of Mark J. O’Connor's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark J. O’Connor with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark J. O’Connor more than expected).

Fields of papers citing papers by Mark J. O’Connor

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark J. O’Connor. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark J. O’Connor. The network helps show where Mark J. O’Connor may publish in the future.

Co-authors

The 25 scholars most cited alongside Mark J. O’Connor, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Mark J. O’Connor Line = papers co-authored together Mark J. O’Connor links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Showing the 20 most-cited of 119 papers — load more, or switch the sort, to bring in the rest.

#	Work
1	Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers New England Journal of Medicine ·Peter C.C. Fong, David S. Boss, Timothy A. Yap, Andrew Tutt, Peijun Wu, Marja Mergui‐Roelvink, Peter G. Mortimer, Helen Swaisland, Alan Lau, Mark J. O’Connor, Alan Ashworth, James Carmichael, Stan B. Kaye, Jan H.M. Schellens, Johann S. de Bono Hit paper breakdown →	2009	2698
2	Targeting the DNA Damage Response in Cancer Molecular Cell ·Mark J. O’Connor Hit paper breakdown →	2015	1075
3	Deficiency in the Repair of DNA Damage by Homologous Recombination and Sensitivity to Poly(ADP-Ribose) Polymerase Inhibition Cancer Research ·Nuala McCabe, Nicholas C. Turner, Christopher J. Lord, Katarzyna Kluzek, Aneta Białkowska, Sally Swift, Sabrina Giavara, Mark J. O’Connor, Andrew Tutt, Małgorzata Z. Zdzienicka, Graeme C.M. Smith, Alan Ashworth Hit paper breakdown →	2006	977
4	High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs Proceedings of the National Academy of Sciences ·Sven Rottenberg, Janneke E. Jaspers, Ariena Kersbergen, Eline van der Burg, Anders O.H. Nygren, Serge A.L. Zander, Patrick W.B. Derksen, Michiel de Bruin, John Zevenhoven, Alan Lau, Robert Boulter, Aaron Cranston, Mark J. O’Connor, Niall M.B. Martin, Piet Borst, Jos Jonkers Hit paper breakdown →	2008	762
5	Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action Science Translational Medicine ·Yves Pommier, Mark J. O’Connor, Johann S. de Bono Hit paper breakdown →	2016	540
6	4-[3-(4-Cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorobenzyl]-2H-phthalazin-1-one: A Novel Bioavailable Inhibitor of Poly(ADP-ribose) Polymerase-1 Journal of Medicinal Chemistry ·Keith Menear, Claire Adcock, Robert Boulter, Xiaoling Cockcroft, Louise Copsey, Aaron Cranston, Krystyna J. Dillon, Jan Drzewiecki, Sheila Garman, Sylvie Gomez, Hashim Javaid, Frank Kerrigan, Charlotte Knights, Alan Lau, Vincent M. Loh, Ian T.W. Matthews, Stephen Moore, Mark J. O’Connor, Graeme C.M. Smith, Niall M.B. Martin	2008	483
7	Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors Cancer Discovery ·Janneke E. Jaspers, Ariena Kersbergen, Ute Boon, Wendy Sol, Liesbeth van Deemter, Serge A.L. Zander, Rinske Drost, Ellen Wientjens, Jiuping Ji, Amal Aly, James H. Doroshow, Aaron Cranston, Niall M.B. Martin, Alan Lau, Mark J. O’Connor, Shridar Ganesan, Piet Borst, Jos Jonkers, Sven Rottenberg	2012	388
8	Improved ATM kinase inhibitor KU-60019 radiosensitizes glioma cells, compromises insulin, AKT and ERK prosurvival signaling, and inhibits migration and invasion Molecular Cancer Therapeutics ·Sarah E. Golding, Elizabeth Rosenberg, Nicholas C.K. Valerie, Isa M. Hussaini, Mark Frigerio, Xiaoling Cockcroft, Wei Yee Chong, Marc Hummersone, Laurent Rigoreau, Keith Menear, Mark J. O’Connor, Lawrence F. Povirk, Timothy Van Meter, Kristoffer Valerie	2009	285
9	Mild hyperthermia inhibits homologous recombination, induces BRCA2 degradation, and sensitizes cancer cells to poly (ADP-ribose) polymerase-1 inhibition Proceedings of the National Academy of Sciences ·Przemek M. Krawczyk, Berina Eppink, Jeroen Essers, Jan Stap, Hans M. Rodermond, Hanny Odijk, Alex N. Zelensky, Chris van Bree, Lukas J.A. Stalpers, Marrije R. Buist, Thomas Soullié, Joost A.P. Rens, Hence J.M. Verhagen, Mark J. O’Connor, Nicolaas A.P. Franken, Timo L.M. ten Hagen, Roland Kanaar, Jacob A. Aten	2011	276
10	The Human Papillomavirus Type 16 E6 Oncoprotein Can Down-Regulate p53 Activity by Targeting the Transcriptional Coactivator CBP/p300 Journal of Virology ·Holger Zimmermann, Roland Degenkolbe, Hans‐Ulrich Bernard, Mark J. O’Connor	1999	265
11	Selective Inhibition of BRCA2-Deficient Mammary Tumor Cell Growth by AZD2281 and Cisplatin Clinical Cancer Research ·Bastiaan Evers, Rinske Drost, Eva Schut, Michiel de Bruin, Eline van der Burg, Patrick W.B. Derksen, Henne Holstege, Xiaoling Liu, Ellen van Drunen, H. Berna Beverloo, Graeme C.M. Smith, Niall M.B. Martin, Alan Lau, Mark J. O’Connor, Jos Jonkers	2008	259
12	PARP Inhibitors: Extending Benefit Beyond BRCA-Mutant Cancers Clinical Cancer Research ·Patrick G. Pilié, Carl M. Gay, Lauren A. Byers, Mark J. O’Connor, Timothy A. Yap	2019	244
13	The overexpression of specialized DNA polymerases in cancer DNA repair ·Mark R. Albertella, Alan Lau, Mark J. O’Connor	2005	211
14	BRD4 Inhibition Is Synthetic Lethal with PARP Inhibitors through the Induction of Homologous Recombination Deficiency Cancer Cell ·Chaoyang Sun, Jun‐Jie Yin, Yong Fang, Jian Chen, Kang Jin Jeong, Xiaohua Chen, Christopher P. Vellano, Zhenlin Ju, Wei Zhao, Dong Zhang, Yiling Lu, Funda Meric‐Bernstam, Timothy A. Yap, Maureen M. Hattersley, Mark J. O’Connor, Huawei Chen, Stephen E. Fawell, Shiaw‐Yih Lin, Guang Peng, Gordon B. Mills	2018	205
15	The orally active and bioavailable ATR kinase inhibitor AZD6738 potentiates the anti-tumor effects of cisplatin to resolve ATM-deficient non-small cell lung cancerin vivo Oncotarget ·Frank P. Vendetti, Alan Lau, Sandra Schamus, Thomas P. Conrads, Mark J. O’Connor, Christopher J. Bakkenist	2015	188
16	Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes British Journal of Cancer ·Darren Hodgson, Brian Dougherty, Zhongwu Lai, Anitra Fielding, Lynda Grinsted, Stuart Spencer, Mark J. O’Connor, Tony W. Ho, Jane Robertson, Jerry S. Lanchbury, Kirsten M. Timms, Alexander Gutin, Maria Orr, Helen Jones, C. Blake Gilks, Chris Womack, Charlie Gourley, Jonathan A. Ledermann, J. Carl Barrett	2018	167
17	A Role for Polymerase η in the Cellular Tolerance to Cisplatin-Induced Damage Cancer Research ·Mark R. Albertella, Catherine Green, Alan R. Lehmann, Mark J. O’Connor	2005	167
18	Inhibition of PARP-1 by Olaparib (AZD2281) Increases the Radiosensitivity of a Lung Tumor Xenograft Molecular Cancer Therapeutics ·Joana M. Senra, Brian A. Telfer, Kim E. Cherry, Cian M. McCrudden, David G. Hirst, Mark J. O’Connor, Stephen R. Wedge, Ian J. Stratford	2011	155
19	ATM Kinase Inhibition Preferentially Sensitizes p53-Mutant Glioma to Ionizing Radiation Clinical Cancer Research ·Laura Biddlestone-Thorpe, Sajjad Muhammad, Elizabeth Rosenberg, Jason M. Beckta, Nicholas C.K. Valerie, Mary Tokarz, Bret R. Adams, Alison F. Wagner, Ashraf Khalil, Donna Gilfor, Sarah E. Golding, Sumitra Deb, David G. Temesi, Alan Lau, Mark J. O’Connor, Kevin S. Choe, Luis F. Parada, Sang Kyun Lim, Nitai D. Mukhopadhyay, Kristoffer Valerie	2013	150
20	Copper(II) Complexes of Salicylic Acid Combining Superoxide Dismutase Mimetic Properties with DNA Binding and Cleaving Capabilities Display Promising Chemotherapeutic Potential with Fast Acting in Vitro Cytotoxicity against Cisplatin Sensitive and Resistant Cancer Cell Lines Journal of Medicinal Chemistry ·Mark J. O’Connor, Andrew Kellett, Malachy McCann, Georgina M. Rosair, Mary McNamara, Orla Howe, Bernadette S. Creaven, Siobhán McClean, Agnieszka Foltyn-Arfa Kia, Denis O′Shea, Michael Devereux	2012	148

About Mark J. O’Connor

Mark J. O’Connor is a scholar working on Oncology, Molecular Biology, Genetics, Pulmonary and Respiratory Medicine and Epidemiology, having authored 119 papers that have together received 13.7k indexed citations. Recurring topics across this work include DNA Repair Mechanisms (63 papers), PARP inhibition in cancer therapy (61 papers), BRCA gene mutations in cancer (17 papers), CRISPR and Genetic Engineering (12 papers), Cancer-related Molecular Pathways (11 papers), Cancer therapeutics and mechanisms (10 papers), Cervical Cancer and HPV Research (8 papers) and Metal complexes synthesis and properties (8 papers). The work is most often cited by research in Oncology (9.0k citations), Reproductive Medicine (1.1k citations), Molecular Biology (8.9k citations), Cancer Research (1.8k citations) and Genetics (2.0k citations). Mark J. O’Connor has collaborated with scholars based in United Kingdom, United States and Singapore. Frequent co-authors include Alan Lau, Johann S. de Bono, Alan Ashworth, Andrew Tutt, Timothy A. Yap, Graeme C.M. Smith, Yves Pommier, Peijun Wu, Peter C.C. Fong and Marja Mergui‐Roelvink. Their work appears in journals such as Cancer Research, Molecular Cancer Therapeutics, Journal of Virology, Clinical Cancer Research and Journal of Clinical Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Mark J. O’Connor

Impact in

Papers in i

In The Last Decade

Mark J. O’Connor

Mark J. O’Connor's Hit Papers

Peers

Countries citing papers authored by Mark J. O’Connor

Fields of papers citing papers by Mark J. O’Connor

All Works

About Mark J. O’Connor

Explore authors with similar magnitude of impact

Papers in